Levosimendan is a pharmacological agent primarily used in the treatment of acute heart failure. It is classified as a calcium sensitizer, which enhances the contractility of the heart muscle without significantly increasing myocardial oxygen demand. This unique mechanism of action distinguishes it from traditional inotropic agents. Levosimendan also possesses vasodilatory properties, which help reduce the workload on the heart and improve blood flow. The substance is typically administered intravenously and has a relatively short half-life, necessitating careful monitoring during treatment. Its chemical structure includes a chiral center, making it a stereoisomer, with the (R)-enantiomer being the active form. Levosimendan is known to bind to troponin C, leading to increased calcium sensitivity and improved cardiac function. Additionally, it has been shown to have potential benefits in terms of renal function and overall patient outcomes in heart failure settings. As with any medication, its use may be associated with side effects, and it should be administered under medical supervision.

Levosimendan

36725-41-4: Levosimendan is a pharmacological agent primarily used in the treatment of acute heart failure. It is classified as a calcium sensitizer, which enhances the contractility of the heart muscle without significantly increasing myocardial oxygen demand. This unique mechanism of action distinguishes it from traditional inotropic agents. Levosimendan also possesses vasodilatory properties, which help reduce the workload on the heart and improve blood flow. The substance is typically administered intravenously and has a relatively short half-life, necessitating careful monitoring during treatment. Its chemical structure includes a chiral center, making it a stereoisomer, with the (R)-enantiomer being the active form. Levosimendan is known to bind to troponin C, leading to increased calcium sensitivity and improved cardiac function. Additionally, it has been shown to have potential benefits in terms of renal function and overall patient outcomes in heart failure settings. As with any medication, its use may be associated with side effects, and it should be administered under medical supervision.

CAS 36725-41-4

Levosimendan

rac-Levosimendan Impurity 25

Ref: 4Z-L-4270